AccuStem Sciences Inc. and EmeritusDX announced the execution of an agreement wherein both companies will jointly manage scientific operations and R&D for AccuStem's product portfolio. Initial plans as part of the collaboration will be to immediately focus on furthering the validation of AccuStem's core offering, StemPrintER, for patients with breast cancer. The proprietary 20-gene test stratifies patients according to their recurrence risk and is intended to measure the "stemness" of tumors, or how much they behave like stem cells, which may indicate the likelihood of cancer progression and response to standard treatment modalities.

While StemPrintER has been shown to outperform the current market leader for risk of recurrence testing in patients with breast cancer, OncotypeDX, this alliance will further establish the utility of the assay in addressing unanswered clinical questions such as identifying which surgical intervention will improve outcomes. EmeritusDX, a pioneering cancer diagnostics and information company, continues its commitment to transforming cancer care through personalised medicine. Operating from their facilities in California and Pennsylvania, EmeritusDX will leverage their top-tier molecular laboratories and a seasoned research and development team to validate the StemPrintER assay.

This crucial collaboration with AccuStem is aimed at showcasing the clinical utility of the test while advancing precision medicine. By joining forces, EmeritusDX and AccuStem strive to provide healthcare providers with actionable insights that drive improved patient outcomes, empowering them with the tools they need to make informed decisions in the fight against cancer. The leadership teams believe this strategic partnership will position StemPrintER for an expeditious launch in breast cancer while bolstering their research and development efforts to expand its indication to other tumor types in the future.